This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Health Winners & Losers: Genentech

Stocks in this article: DNADNDNIMCL

Updated from 3:28 p.m. EDT

Health stocks nudged up slightly but then reversed in the second half of the day Wednesday, while analysts issued upgrades to some underpriced biotech and pharma stocks.

First, in potential biotech merger news, Genentech (DNA), which has been presented with an $89-a-share proposal from Swiss pharma company Roche, dipped into the $75 range midday Wednesday. This suggests investors are still concerned that Roche won't be able to arrange financing for the deal, despite the company's confidence. Shares did find some relief Wednesday, rallying to $80.56 before the close.

For reference, Genentech closed at $81.82 a share the last trading day before Roche announced its buyout proposal.

Meanwhile, ImClone (IMCL) shares were trading down 0.2% at $66.85 amid Eli Lilly's (LLY) proposed takeover for $70 a share -- an offer that's reportedly not subject to financing.

Both ImClone and Genentech are components of the Amex biotechnology index, which was up 1.19% midday only to reverse to a loss of 0.67% by the market's close.

Fellow component Celgene (CELG) added $2.07, or 3.7%, to $57.95 Wednesday. Cowen and Co. analyst Rachel McMinn upgraded Celgene to outperform from neutral. McMinn said the current price doesn't fully account for the company's expected growth over the next few years.

In other news, Merrill Lynch upgraded Pfizer (PFE) and Bristol-Myers Squibb (BMY) to underperform from buy. Pfizer was up 1.25% to $17.87 midday, only to settle into a loss of 2.9% later in the day. Bristol was up 3.13% to $19.43 in midday trading, but also settled back to a gain of just 0.5% at $18.94.

Also, Oppenhiemer initiated coverage on medical diagnostics company Myriad Genetics (MYGN) with an outperform rating and a $92 price target. That stock added 4.7% at one point, but was trading up roughly 2.7% later in the day.

Elsewhere, Omrix Biopharmaceuticals (OMRI) shares tacked on 5.5% to $18.25 by midday, hanging on to a 3% gain later in the day. The company said that according to interim results from a midstage trial, its Fibrin Pad product was superior to Johnson & Johnson's (JNJ)Surgicel for stopping mild to moderate soft tissue bleeding during certain surgeries.

And, last, Dendreon (DNDN) shares continued to drop in the morning on higher than average volume for a second day after the Monday release of interim data on the company's prostate cancer vaccine Provenge. Dendreon's infamously volatile shares were down as much as 5% early Wednesday, but settled back to the flat line. The stock lost 15% the day prior after it gained 33% on Monday.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,810.06 +91.06 0.51%
S&P 500 2,063.50 +10.75 0.52%
NASDAQ 4,712.97 +11.1030 0.24%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs